Skip to content
Review

Regulation of PI3K Signaling by lncRNAs in Breast Cancer: A Mini-Review.

Aug 2026 · Mini-Reviews in Medical Chemistry · Vol 26 · 0 citations
Medicine

TL;DR

This mini-review synthesizes recent evidence on lncRNAs targeting the PI3K/AKT/mTOR cascade in breast cancer, summarizing molecular mechanisms, functional consequences for proliferation, invasion, and therapy resistance, and available in vitro and in vivo evidence.

Abstract

Despite remarkable advancements, the treatment of breast cancer remains a serious challenge. In recent decades, extensive studies have been conducted to identify new therapeutic targets for the treatment of breast cancer. Among these therapeutic targets that have gained attention in recent years are lncRNAs. These molecules appear to affect proliferation, metastasis, and drug resistance in cancer cells by regulating multiple signaling pathways. Among the signaling pathways implicated in breast cancer, the PI3K/AKT/mTOR pathway is one of the most important. Given the frequent dysregulation of the PI3K/AKT/mTOR pathway in breast cancer, numerous recent studies have investigated its interplay with lncRNAs. Emerging evidence indicates that lncRNAs regulate the PI3K/AKT/mTOR pathway by modulating microRNA availability, influencing transcriptional programs, and serving as molecular platforms for chromatin-modifying complexes. This mini-review synthesizes recent evidence on lncRNAs targeting the PI3K/AKT/mTOR cascade in breast cancer, summarizing molecular mechanisms, functional consequences for proliferation, invasion, and therapy resistance, and available in vitro and in vivo evidence. Representative oncogenic lncRNAs (e.g., HOTAIR, DANCR, and LINC01133) and tumor-suppressive lncRNAs (e.g., MEG3 and ZFAS1) are discussed, together with their potential as therapeutic targets. Finally, the current challenges and future perspectives for integrating lncRNAtargeted approaches with PI3K pathway inhibition in breast cancer therapy are highlighted.

View source

Similar papers

Review Open access Sep 2026

From epigenetics to metastasis: Multifaceted roles of lncRNAs in gastric cancer

This review provides a comprehensive overview of the current understanding of lncRNA-mediated regulation of EMT and metastasis in gastric cancer and provides insights into the complex regulatory networks governed by lncRNAs, highlighting their translational potential in improving GC management.

M. Saadh, A. K. Bishoyi, R. Roopashree et al. · 0 citations
Review Open access Aug 2026

m6A RNA methylation in breast cancer: from epitranscriptomic regulation to therapeutic targeting.

This review systematically summarize the functional roles of m6A regulators, including writers, erasers, and readers, in breast cancer biology and highlights the emerging clinical potential of m6A regulators as diagnostic and prognostic biomarkers, as well as therapeutic targets for overcoming drug resistance.

Zilong Chen, Chi Zhou, Zhuo-Run Song et al. · 0 citations
Review Aug 2026

The Pivotal Role of miR-770 in Solid Tumors Carcinogenesis

MiR-770 has been introduced as a potential marker in the prognosis of various cancers as well as in the early identification of tumor formation, progression, and metastasis.

Mohsen Davari, Pooran Ghiasizadeh, Mozhgan Mondeali et al. · 0 citations
Review Oct 2026

RIPK1 kinase and scaffold activities in tumor cell fate and therapy.

Receptor-interacting protein kinase 1 (RIPK1) plays a pivotal role in regulating cell survival and death, thereby exerting complex and multifaceted functions in the initiation and progression of cancer. Its expression is frequently dysregulated across diverse malignancies and correlates strongly with poor prognosis, hi...

Jing-Yu Luo, Shu-Ya Song, Ze-Kun Li et al. · 0 citations
Review Sep 2026

SET Oncoprotein in Gastric Cancer: A Master Regulator of PP2A Suppression and Tumor Progression

Therapeutic modulation of the SET-PP2A axis may provide a novel strategy for suppressing tumor progression and improving treatment outcomes, and further mechanistic studies and welldesigned clinical investigations are required to establish the therapeutic relevance of SET targeting and facilitate its integration into p...

Rohit Das, Shikha Yadav, Sudeshna Das et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.